Why Jaguar Health Stock Is Up Today
Why Jaguar Health Stock Is Up Today
Jaguar Health, Inc. (NASDAQ:JAGX) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreement with Venture Life Group PLC.
The Details:
The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is used for the treatment of oral mucositis, also called "chemo mouth."
"We are very happy to have executed the in-license agreement for Gelclair – and thus to have initiated Jaguar's commercial footprint in our core focus area of cancer supportive care," said Lisa Conte, Jaguar's president and CEO.
Jaguar Health shares are moving on heavy trading volume following the announcement with more than 240 million shares already traded in the session. According to data from Benzinga Pro, the stock's 100-day average volume is 46.306 million shares.
Related News: What's Going On With Rivian Automotive Stock?
Should I Sell My JAGX Stock?
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Jaguar Health have decreased by 68.97% in the past year. An investor who bought shares of Jaguar Health at the beginning of the year would make a profit of $0.04 per share if they sold it today. The stock has risen 172.33% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital gain of $0.05.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health stock currently has an RSI of 70.7, indicating overbought conditions.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
JAGX Price Action: According to Benzinga Pro, Jaguar Health shares are up 49.5% at 18 cents at the time of publication Tuesday.
Image from Shutterstock
Jaguar Health, Inc. (NASDAQ:JAGX) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreement with Venture Life Group PLC.
捷豹健康公司（納斯達克股票代碼：JAGX）週二股價走高，此前該公司宣佈已與Venture Life Group PLC簽署了爲期5年的獨家許可協議。
The Details:
細節：
The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is used for the treatment of oral mucositis, also called "chemo mouth."
該許可協議適用於風險人壽經美國食品藥品管理局批准的處方產品Gelclair的美國市場。Gelclair用於治療口腔粘膜炎，也稱爲 “化療口”。
"We are very happy to have executed the in-license agreement for Gelclair – and thus to have initiated Jaguar's commercial footprint in our core focus area of cancer supportive care," said Lisa Conte, Jaguar's president and CEO.
捷豹總裁兼首席執行官麗莎·孔戴錶示：“我們很高興簽署了Gelclair的許可協議，從而啓動了捷豹在癌症支持治療的核心重點領域的商業版圖。”
Jaguar Health shares are moving on heavy trading volume following the announcement with more than 240 million shares already traded in the session. According to data from Benzinga Pro, the stock's 100-day average volume is 46.306 million shares.
宣佈後，捷豹健康的股票交易量保持強勁，該交易日已經交易了超過2.4億股股票。根據Benzinga Pro的數據，該股的100天平均成交量爲4630.6萬股。
Related News: What's Going On With Rivian Automotive Stock?
相關新聞： Rivian Automotive 股票怎麼了？
Should I Sell My JAGX Stock?
我應該賣出我的 JAGX 股票嗎？
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
在決定持有或出售股票時，投資者應考慮其時間範圍、未實現收益和總回報。
Shares of Jaguar Health have decreased by 68.97% in the past year. An investor who bought shares of Jaguar Health at the beginning of the year would make a profit of $0.04 per share if they sold it today. The stock has risen 172.33% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital gain of $0.05.
在過去的一年中，捷豹健康的股價下降了68.97％。年初購買捷豹健康股票的投資者如果今天出售，將獲得每股0.04美元的利潤。該股在過去一個月中上漲了172.33％，這意味着在3月1日購買股票的投資者將獲得0.05美元的資本收益。
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health stock currently has an RSI of 70.7, indicating overbought conditions.
投資者也可以考慮市場動態。相對強弱指數可用於表明股票是超買還是超賣。捷豹健康股票目前的相對強弱指數爲70.7，這表明存在超買情況。
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
要訪問高級製圖和分析工具以及股票數據，請查看 Benzinga PRO。免費試用。
JAGX Price Action: According to Benzinga Pro, Jaguar Health shares are up 49.5% at 18 cents at the time of publication Tuesday.
JAGX價格走勢：根據Benzinga Pro的數據，捷豹健康股價在週二發佈時上漲了49.5％，至18美分。
Image from Shutterstock
圖片來自 Shutterstock
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧